Verition Fund Management
SPRY icon

Verition Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

Verition Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
+30,750
New +$265K ﹤0.01% 1797
2025
Q2 		– Sell
-27,681
Closed -$348K – 3848
2025
Q1 		$348K Buy
27,681
+12,243
+79% +$147K ﹤0.01% 2788
2024
Q4 		$163K Buy
15,438
+4,975
+48% +$69.7K ﹤0.01% 3019
2024
Q3 		$152K Sell
10,463
-16,462
-61% -$196K ﹤0.01% 2940
2024
Q2 		$229K Buy
+26,925
New +$239K ﹤0.01% 2510
2023
Q2 		– Sell
-23,869
Closed -$155K – 2522
2023
Q1 		$155K Buy
+23,869
New +$183K ﹤0.01% 1831

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Verition Fund Management's SPRY Position: Q2 2026 in Review

Verition Fund Management opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 30,750 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #1797 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in SPRY as recently as Q1 2025.

Verition Fund Management first reported a position in SPRY in Q1 2023 and has held it in 6 quarters since. The position peaked at $348K in Q1 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Verition Fund Management held 30,750 shares of ARS Pharmaceuticals worth $246K as of Q2 2026.
  • ARS Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1797 holding.
  • Verition Fund Management first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Verition Fund Management's ARS Pharmaceuticals position peaked at $348K in Q1 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.